December 2, 2021
Life Sciences
  • GlaxoSmithKline PLC and Vir Biotechnology Inc. said their COVID-19 antibody treatment was effective against the omicron variant in early lab tests. The drugmaker said that lab tests of the mutations found in the variant showed the drug is still active against the virus. It is now conducting in vitro experiments to confirm the response against a combination of all the omicron mutations. (Article here)